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Introduction	
Worldwide,	some	40	million	adults	have	Alzheimer’s	disease	(AD)	and	several	hundred	
million	may	be	at	elevated	risk	for	AD	by	virtue	of	genetic	risk,	cerebrovascular	disease,	
comorbid	illnesses	such	as	diabetes	or	depression,	mild	cognitive	impairment	(MCI)	and/or	
silent	buildup	of	cortical	AD	pathology	(1).		Despite	extensive	research,	there	are	no	
pharmacological	treatments	with	more	than	minimal	efficacy	for	mild	AD,	and	prevention	
strategies	are	not	established.	
	 	The	COVID-19	pandemic	has	transformed	mobile	health	applications	and	telemedicine	
from	nice	to	have	tools	into	essential	healthcare	infrastructure	(2-4).		This	need	is	particularly	
great	for	the	elderly	who,	due	to	their	greater	risk	for	infection,	may	avoid	medical	facilities	or	
be	required	to	self-isolate.	These	are	also	the	very	groups	at	highest	risk	for	cognitive	decline.		
For	example,	during	the	COVID-19	pandemic	artificially	intelligent	conversational	agents	were	
employed	by	hospitals	and	government	agencies	(such	as	the	CDC)	to	field	queries	from	
patients	about	symptoms	and	treatments	(3).	Digital	health	tools	also	proved	invaluable	to	
provide	neuropsychiatric	and	psychological	self-help	to	people	isolated	at	home	or	in	
retirement	centers	and	nursing	homes	(2-4).			
	
Computerized	Cognitive	Training	
Computerized	cognitive	training	(CCT)	is	one	such	application	of	digital	health	in	which	
individuals	can	access	gamified,	engaging,	cognitive	exercises	from	their	own	computers	or	
mobile	devices	anytime	anywhere	(5-15).	These	exercises	can	be	targeted	to	improve	overall	
cognition	or	specific	domains	(such	as	learning	and	memory,	attention,	speed,	executive	
functioning),	as	well	as	daily	living	skills	such	as	financial	knowledge	or	driving	performance	(5-
15).	They	can	potentially	be	adjusted	based	on	response	via	self-administered	cognitive	tests,	
and	adherence	supervised	remotely,	as	needed,	by	a	physician	or	psychologist.	There	are	over	
two-dozen	CCT	programs	on	the	market	and	consumer	demand	is	large	–	tens	of	millions	of	
people	in	dozens	of	countries	have	accessed	CCT	to	date	(5).					
While	popular,	scientific	opinion	regarding	CCT	has	at	times	been	divided.	In	2014,	two	
groups	with	expertise	in	the	field	expressed	conflicting	opinions	on	the	effectiveness	of	CCT	
based	on	the	same	evidence	(6,	7).	While	one	group	claimed	there	was	“little	evidence	that	
playing	brain	games	improved	underlying	broad	cognitive	abilities”,	the	other	retorted	that	"a	
substantial	and	growing	body	of	evidence	shows	that	certain	cognitive	training	regimens	can	
significantly	improve	cognitive	function,	including	in	ways	that	generalize	to	everyday	life.”	
Subsequently,	Simons	et	al.	criticized	many	of	the	industry-sponsored	CCT	studies	on	various	
methodological	limitations	(8).	In	a	rebuttal,	Harvey	et	al.	noted	that	the	critics	may	have	
prematurely	come	to	a	wrong	conclusion	–	they	cited	factors	such	as	incorrect	definitions	of	
CCT	and	described	supportive	evidence	from	meta-analyses	and	large	RCTs	(8).	Likewise,	while	
an	initial	online	study	by	Owen	et	al	(9)	did	not	find	any	benefits	of	CCT	in	younger	adults,	a	
subsequent	study	of	2912	older	adults	by	the	same	group	reported	that	CCT	had	benefits	on	
both	cognition	and	daily	activities	(10).	
	
Clinical	Trials	of	CCT	in	Aging	and	MCI		
The	scientific	rationale	to	develop	CCT	for	treating	MCI	is	sound	–	a	large	body	of	
observational	research	suggest	that	being	cognitively	active	may	reduce	the	risk	for	dementia	
and	experimental	studies	show	that	aging	brains	retain	a	capacity	for	neuroplasticity	(reviewed	
in	5,	11-14).		
There	is	now	evidence	from	relatively	large	well-controlled	trials	to	support	both	
efficacy	and	safety.	For	example,	the	NIH-funded,	Advanced	Cognitive	Training	for	Independent	
and	Vital	Elderly	(ACTIVE)	Trial	of	2,832	older	people,	assigned	people	to	3	forms	of	training	–	
memory,	reasoning	and	speed	–	versus	a	control.		The	memory	group	showed	no	benefits.	But	
five	years	after	initial	training,	the	reasoning	group	self-reported	fewer	daily-living	problems,	
whereas	speed-of-processing	training	resulted	in	fewer	at-fault	automobile	accidents	and	a	
smaller	decline	in	health-related	quality	of	life	(12).		Further,	at	10-year	follow	up,	those	on	the	
computerized	speed	training	arm	had	a	29%	reduction	in	incident	dementia	rates	(13).	A	meta-
analyses	of	52	studies	comprising	4,885	cognitively	healthy	older	adults,	noted	small	to	
moderate	beneficial	effect	sizes	for	CCT	in	comparison	to	control	groups	in	the	domains	of	
verbal	memory,	nonverbal	memory,	working	memory,	processing	speed,	and	visuospatial	skills	
(14).	This	study	also	found	that	group-based	training	was	more	efficacious	than	home-based	
training	-	suggesting	that	future	home	based	CCT	may	need	to	be	augmented	with	greater	
remote	supervision	and	interactions	via	social	media	(14).				A	meta-analysis	of	18	studies	of	
CCT	for	MCI	(N=690)	found	small	to	moderate	improvements	in	global	cognition,	memory	and	
working	memory	(11).		The	largest	effect	size	was	on	working	memory.		Whether	these	
improvements	result	in	long-term	transfer	to	clinically	meaningful	benefits	and	lowered	rates	of	
progression	to	dementia	is	not	known	and	require	further	study.	(11).			
There	is	also	evidence	that	the	effectiveness	of	CCT	in	subjects	at	risk	for	AD	could	be	
improved	by	supplementing	cognitive	training	with	other	tools	such	as	physical	exercise,	diet,	
vascular	risk	reduction,	neuromodulation	or	pharmacotherapy.	For	example,	Lenze	et	al	
reported	that	the	addition	of	a	serotonin	modulator/stimulator	drug,	vortioxetine,	could	
improve	the	efficacy	of	CCT	in	MCI	(17).		Two	studies	that	examined	the	effects	of	combining	
physical	and	cognitive	training	in	MCI	reported	mixed	results	(15,	16).		Singh	et	al,	using	a	2x	2	
design,	found	that	CCT	improved	memory	in	MCI	at	6	months	but	did	not	augment	the	effects	
of	exercise	(15).		In	contrast,	the	40-week	population	study	by	Shimada	et	al	(16)	of	945	MCI	
subjects	reported	that	combined	CCT	and	physical	exercise	improved	memory	and	nonmemory	
domains,	and	reduced	medial	temporal	lobe	atrophy	in	amnestic	MCI	(16).		Lastly,	the	two-year	
FINGER	randomized	controlled	trial	of	1260	older	adults	showed	that	a	multi-domain	lifestyle	
intervention,	comprising	CCT	as	one	of	the	components,	slowed	cognitive	decline	(18).		
	
	
	
Software	as	a	Medical	Device			
The	International	Medical	Device	Regulators	Forum	(IMDRF)	for	software	as	a	medical	
device	(SaMD)	proposed	consensus	guidelines	for	what	constitutes	a	mobile	medical	app	(i.e.	
digital	therapeutic)	versus	a	wellness	app	(19).	These	guidelines	stated	that	a	software	app	
intended	to	treat	or	prevent	a	serious	disease	would	have	to	conduct	well-controlled	clinical	
trials	to	prove	efficacy	and	seek	pre-marketing	authorization	(PMA)	from	a	regulatory	agency.	
Recently,	prescription	digital	therapeutics	have	been	cleared	by	the	US	Food	and	Drug	
Administration	(FDA)	for	use	in	substance	abuse	and	sleep	disorders,	and	apps	for	other	
diseases	are	in	development	(20).	Per	these	guidelines,	CCT	that	is	marketed	for	treating	MCI	or	
preventing	AD	would	be	viewed	as	a	medical	device	and	subject	to	pre-marketing	regulatory	
oversight.	CCT	intended	for	use	as	a	general	wellness	tool	to	improve	mental	speed	would	likely	
not	be	subject	to	such	oversight.						
	
Advancing	CCT	as	a	Digital	Brain	Therapeutic				
We	believe	the	most	efficient	regulatory	path	for	CCT	is	to	seek	a	marketing	indication	
for	the	symptomatic	treatment	of	MCI	or	very	mild	AD	dementia.		Such	a	path	would	be	
supported	by	the	large	public	health	threat	posed	by	AD,	the	high	failure	rate	of	investigational	
drug	trials	and	the	urgent	need	for	scalable,	low	risk,	cost-effective,	home-based	preventive	
treatments.	The	small	to	moderate	effect	sizes	seen	in	MCI	CCT	trials	to	date	are	likely	to	be	
similar	to	those	expected	in	ongoing	anti-amyloid	or	anti-tau	trials.	Further,	the	safety	of	CCT	is	
superior	to	most	biologics/drugs	being	studied	for	MCI	and	the	risk	is	minimal.			
While	regulatory	approaches	for	devices	often	differ	from	that	of	drugs,	recent	FDA	
draft	guidelines	for	acceptable	outcomes	in	early	AD	trials	of	investigational	drugs	(21)	provide	
a	roadmap	for	CCT.	The	FDA	guidance	categorizes	early	AD	into	three	stages	–	Stage	1	
(pathological	changes	but	no	clinical	deficits),	Stage	2	(mild	cognitive	deficits	but	no	measurable	
functional	deficits),	and	Stage	3	(measurable	cognitive	and	functional	deficits).		Stages	2	and	3	
are	analogous	to	early	MCI	and	late-MCI.			
The	above	guidance	suggests	that	in	Stage	1	one	or	more	biomarkers	could	serve	as	a	
primary	basis	for	accelerated	approval	with	the	requirement	for	a	post-approval	confirmatory	
clinical	study.		In	Stage	2,	one	or	more	neuropsychological	tests	(either	effect	on	multiple	tests	
or	a	large	effect	on	a	single	test)	could	serve	as	the	basis	for	approval.	In	Stage	3,	a	single	
integrated	scale	that	measures	both	daily	function	and	cognitive	effects	(e.g.	Clinical	Dementia	
Rating	Scale)	could	serve	as	evidence	of	efficacy.			
Although	the	overall	literature	shows	CCT	to	be	safe	with	a	high	likelihood	of	cognitive	
efficacy	in	aging	and	MCI,	the	lack	of	positive,	regulatory	quality	trials	is	the	major	limitation.		
The	bar	for	clearance	of	a	software	device	is	often	lower	than	that	of	a	drug;	hence	it	is	likely	
regulatory	agencies	may	view	the	existing	studies	of	CCT	in	aging	and	MCI	(such	as	those	cited	
in	5-17)	as	supportive	and	may	require	only	a	single,	methodologically	rigorous,	relatively	short	
(e.g.	24-week)	trial	to	gain	such	an	indication.		Given	the	lack	of	a	predicate	or	product	code,	
CCT	for	MCI	would	likely	be	viewed	by	the	FDA	as	a	Class	III	device	(22);	however,	we	believe	
that	a	de-novo	application	to	request	re-classification	of	CCT	as	a	lower	risk	Class	II	device	could	
be	successful.		CCT	manufacturers	should	seek	advice	from	regulatory	agencies	before	and	
during	this	process	as	is	done	with	drugs	(19).	Alternatively,	CCT	manufacturers	seeking	an	MCI	
indication	could	also	utilize	the	FDA’s	digital	software	pre-certification	(Pre-Cert)	program.		
Such	a	path	would	increase	trust	among	clinicians,	consumers	and	payers.		
To	date,	however,	CCT	products	aimed	at	the	elderly	have	chosen	the	less	risky	path	of	
going	directly	to	consumers	as	a	“wellness”	product	–	suggesting	the	need	for	incentives	such	
as	market	exclusivity	or	preferential	formulary	access.		Alternatively	a	regulatory	quality	trial	
could	also	be	conducted	in	the	public	interest	through	a	public-private	partnership	involving	
one	or	more	CCT	companies	or	via	a	government	grant.		For	example,	our	group	is	currently	
conducting	an	18-month	randomized	trial	of	CCT	versus	active	control	in	carefully	selected	MCI	
patients	with	clinically	meaningful	cognitive	(ADAS-Cog),	functional	(FAQ,	UPSA),	neuronal	loss	
(hippocampal	volume)	and	disease	modifying	(progression	to	dementia)	outcomes	(23).		
Given	the	millions	of	elderly	already	doing	CCT	at	home,	it	would	also	be	insightful	to	
analyze	existing	large	registries	to	examine	real	world	outcomes	consistent	with	the	FDA’s	total	
product	lifecycle	approach	(22).	Three	areas	of	real	world	health	analytics	(RWHA)	would	be	
relevant	for	CCT	–	1)	patient	reported	outcomes	such	as	daily	activities;	2)	user	experience	
analytics	such	as	engagement	and	compliance;	3)	product	performance	(reliability,	privacy	and	
cybersecurity).	Updates	on	real	world	performance	could	be	provided	quarterly	to	public	and	
regulators.			
For	clinicians	and	the	general	public	to	be	willing	to	use	CCT	as	a	primary	treatment	
modality,	convincing	evidence	in	well-controlled	trials	with	a	clear	focus	on	MCI,	for	example,	
would	be	helpful.	Future	research	to	clarify	the	role	of	augmenting	agents,	such	as	off-label	
medications	(e.g.	vortioxetine),	cholinesterase	inhibitors,	physical	exercise	and	other	non-
pharmacologic	interventions,	for	CCT	to	achieve	maximum	efficacy	as	a	cognitive	enhancing	
strategy	would	also	be	useful.		Future	studies	could	also	examine	it’s	utility	in	combination	with	
anti-amyloid	or	anti-tau	agents.			
The	COVID-19	pandemic	has	illustrated	the	demand	for	digital	tools	across	the	entire	
spectrum	of	healthcare.		Reimbursement	and	regulatory	burdens	faced	by	digital	tools	before	
the	pandemic	have	begun	to	diminish.		Post-pandemic,	companies	that	integrate	digital	
therapeutics	with	other	modalities	(e.g.	digital	diagnostics,	digital	pharmacy,	live	consults	via	
tele-medicine)	will	best	provide	a	seamless	experience	for	consumers.		A	patient-centered,	real	
world	health	data	sharing	platform	that	can	collect	and	aggregate	siloed	data	sources	across	
multiple	health	systems	has	recently	been	demonstrated		(24).	These	lessons	are	highly	
relevant	to	optimize	CCT	as	a	clinical	tool	in	MCI.			
In	summary,	we	believe	that	it	is	an	important	time	for	the	field	to	advance	CCT	from	a	
wellness	product	to	a	well-integrated,	digital	brain	therapeutic	via	an	appropriate	regulatory	
pathway.	If	efficacy	is	established	in	MCI,	then	CCT	could	be	combined	with	specific	self-rated	
cognitive	and	functional	assessment	scales	as	well	as	other	clinical	care	options	to	help	millions	
of	elderly	both	during	pandemics	and	in	normal	times.		
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